{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T15:16:21Z","timestamp":1792163781144,"version":"4.4.0"},"reference-count":51,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revista de Psiquiatr\u00eda  y Salud Mental"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.rpsm.2018.03.007","type":"journal-article","created":{"date-parts":[[2018,6,28]],"date-time":"2018-06-28T07:10:01Z","timestamp":1530169801000},"page":"163-169","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Uso de asenapina en la pr\u00e1ctica cl\u00ednica: recomendaciones de un panel de expertos"],"prefix":"10.1016","volume":"12","author":[{"given":"Eduard","family":"Vieta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Manuel","family":"Montes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Iborra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfonso","family":"Mozos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"S\u00e1ez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Benabarre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rpsm.2018.03.007_bib0260","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/S0140-6736(13)61611-6","article-title":"Global burden of disease attributable to mental and substance use disorders: Findings from the Global Burden of Disease Study 2010","volume":"382","author":"Whiteford","year":"2013","journal-title":"Lancet."},{"key":"10.1016\/j.rpsm.2018.03.007_bib0265","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1016\/j.euroneuro.2013.04.001","article-title":"The increasing burden of mental and neurological disorders","volume":"23","author":"Catal\u00e1-L\u00f3pez","year":"2013","journal-title":"Eur Neuropsychopharmacol."},{"key":"10.1016\/j.rpsm.2018.03.007_bib0270","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1016\/S0140-6736(15)00241-X","article-title":"Bipolar disorder","volume":"387","author":"Grande","year":"2016","journal-title":"Lancet."},{"key":"10.1016\/j.rpsm.2018.03.007_bib0275","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1017\/S1092852916000869","article-title":"Mixed features in bipolar disorder","volume":"22","author":"Sol\u00e9","year":"2017","journal-title":"CNS Spectr."},{"key":"10.1016\/j.rpsm.2018.03.007_bib0280","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jad.2005.01.004","article-title":"Treatment guidelines for bipolar disorder: A critical review","volume":"86","author":"Fountoulakis","year":"2005","journal-title":"J Affect Disord."},{"key":"10.1016\/j.rpsm.2018.03.007_bib0285","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1177\/0269881116636545","article-title":"Evidence-based guidelines for treating bipolar disorder: Revised third edition recommendations from the British Association for Psychopharmacology","volume":"30","author":"Goodwin","year":"2016","journal-title":"J Psychopharmacol."},{"key":"10.1016\/j.rpsm.2018.03.007_bib0290","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s40263-015-0235-1","article-title":"Pharmacotherapy of acute mania: Monotherapy or combination therapy with mood stabilizers and antipsychotics?","volume":"29","author":"Grande","year":"2015","journal-title":"CNS Drugs."},{"key":"10.1016\/j.rpsm.2018.03.007_bib0295","unstructured":"AEMPS. Sycrest. Ficha T\u00e9cnica. 2010 [consultado 15 May 2017]. Disponible en: http:\/\/www.ema.europa.eu\/docs\/es_ES\/document_library\/EPAR_-_Product_Information\/human\/001177\/WC500096895.pdf"},{"key":"10.1016\/j.rpsm.2018.03.007_bib0300","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1111\/j.1399-5618.2009.00748.x","article-title":"A 3-week, randomized, placebo-controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states","volume":"11","author":"McIntyre","year":"2009","journal-title":"Bipolar Disord."},{"key":"10.1016\/j.rpsm.2018.03.007_bib0305","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jad.2009.12.028","article-title":"Asenapine in the treatment of acute mania in bipolarI disorder: A randomized, double-blind, placebo-controlled trial","volume":"122","author":"McIntyre","year":"2010","journal-title":"J Affect Disord."},{"key":"10.1016\/j.rpsm.2018.03.007_bib0310","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1097\/JCP.0b013e31823f872f","article-title":"Asenapine as adjunctive treatment for acute mania associated with bipolar disorder: Results of a 12-week core study and 40-week extension","volume":"32","author":"Szegedi","year":"2012","journal-title":"J Clin Psychopharmacol."},{"key":"10.1016\/j.rpsm.2018.03.007_bib0315","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.jad.2013.04.025","article-title":"DSM-5 mixed specifier for manic episodes: Evaluating the effect of depressive features on severity and treatment outcome using asenapine clinical trial data","volume":"150","author":"McIntyre","year":"2013","journal-title":"J Affect Disord."},{"key":"10.1016\/j.rpsm.2018.03.007_bib0320","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/1471-244X-11-101","article-title":"Effects of asenapine on depressive symptoms in patients with bipolarI disorder experiencing acute manic or mixed episodes: A post hoc analysis of two 3-week clinical trials","volume":"11","author":"Szegedi","year":"2011","journal-title":"BMC Psychiatry."},{"key":"10.1016\/j.rpsm.2018.03.007_bib0325","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jad.2012.07.013","article-title":"Effect of asenapine on manic and depressive symptoms in bipolarI patients with mixed episodes: Results from post hoc analyses","volume":"145","author":"Azorin","year":"2013","journal-title":"J Affect Disord."},{"key":"10.1016\/j.rpsm.2018.03.007_bib0330","doi-asserted-by":"crossref","first-page":"728","DOI":"10.4088\/JCP.13m08827","article-title":"Effects of asenapine in bipolarI patients meeting proxy criteria for moderate-to-severe mixed major depressive episodes: A post hoc analysis","volume":"76","author":"Berk","year":"2015","journal-title":"J Clin Psychiatry."},{"key":"10.1016\/j.rpsm.2018.03.007_bib0335","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1177\/2045125316674698","article-title":"Does the efficacy of asenapine in bipolar disorder increase in the presence of comorbidity with a substance use disorder? A naturalistic study","volume":"7","author":"De Filippis","year":"2017","journal-title":"Ther Adv Psychopharmacol"},{"key":"10.1016\/j.rpsm.2018.03.007_bib0340","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.rpsm.2010.10.003","article-title":"Asenapine: A new focus on the treatment of mania","volume":"4","author":"Cruz","year":"2011","journal-title":"Rev Psiquiatr Salud Ment."},{"key":"10.1016\/j.rpsm.2018.03.007_bib0345","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.rpsm.2015.03.003","article-title":"Personalised medicine applied to mental health: Precision psychiatry","volume":"8","author":"Vieta","year":"2015","journal-title":"Rev Psiquiatr Salud Ment."},{"key":"10.1016\/j.rpsm.2018.03.007_bib0350","unstructured":"Food and Drug Administration (FDA). Saphris (Asenapine). Highlights of Prescribing Information. 2009 [consultado 15 May 2017]. Disponible en: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/022117s017s018s019lbl.pdf"},{"key":"10.1016\/j.rpsm.2018.03.007_bib0355","series-title":"Stahl's Illustrated Antipsychotics: Treating Psychosis Mania and Depression","author":"Stahl","year":"2010"},{"key":"10.1016\/j.rpsm.2018.03.007_bib0360","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1177\/0269881107082944","article-title":"Asenapine: A novel psychopharmacologic agent with a unique human receptor signature","volume":"23","author":"Shahid","year":"2009","journal-title":"J Psychopharmacol."},{"key":"10.1016\/j.rpsm.2018.03.007_bib0365","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1177\/2045125311430112","article-title":"Receptor mechanisms of antipsychotic drug action in bipolar disorder \u2014 focus on asenapine","volume":"1","author":"Reynolds","year":"2011","journal-title":"Ther Adv Psychopharmacol"},{"key":"10.1016\/j.rpsm.2018.03.007_bib0370","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.jad.2010.04.005","article-title":"Asenapine for long-term treatment of bipolar disorder: A double-blind 40-week extension study","volume":"126","author":"McIntyre","year":"2010","journal-title":"J Affect Disord."},{"key":"10.1016\/j.rpsm.2018.03.007_bib0375","series-title":"Manual diagn\u00f3stico y estad\u00edstico de los trastornos mentales-DSM 5","year":"2014"},{"key":"10.1016\/j.rpsm.2018.03.007_bib0380","first-page":"409","article-title":"Asenapine effects on individual Young Mania Rating Scale items in bipolar disorder patients with acute manic or mixed episodes: A pooled analysis","volume":"9","author":"Cazorla","year":"2013","journal-title":"Neuropsychiatr Dis Treat."},{"key":"10.1016\/j.rpsm.2018.03.007_bib0385","doi-asserted-by":"crossref","first-page":"251","DOI":"10.2165\/11206700-000000000-00000","article-title":"Asenapine: A review of its use in the management of mania in adults with bipolarI disorder","volume":"25","author":"Chwieduk","year":"2011","journal-title":"CNS Drugs."},{"key":"10.1016\/j.rpsm.2018.03.007_bib0390","unstructured":"Grupo de Trabajo de la Gu\u00eda de Pr\u00e1ctica Cl\u00ednica sobre Trastorno Bipolar. Gu\u00eda de Pr\u00e1ctica Cl\u00ednica sobre Trastorno Bipolar. Madrid: Plan de Calidad para el Sistema Nacional de Salud del Ministerio de Sanidad, Servicios Sociales e Igualdad. Universidad de Alcal\u00e1. Asociaci\u00f3n Espa\u00f1ola de Neuropsiquiatr\u00eda, editor. UAH\/AEN; 2012."},{"key":"10.1016\/j.rpsm.2018.03.007_bib0395","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.eurpsy.2015.01.003","article-title":"Asenapine prescribing patterns in the treatment of manic in-and outpatients: Results from the MANACOR study","volume":"30","author":"Grande","year":"2015","journal-title":"Eur Psychiatry."},{"key":"10.1016\/j.rpsm.2018.03.007_bib0400","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1002\/bdd.718","article-title":"Effect of absorption site on the pharmacokinetics of sublingual asenapine in healthy male subjects","volume":"31","author":"Gerrits","year":"2010","journal-title":"Biopharm Drug Dispos."},{"key":"10.1016\/j.rpsm.2018.03.007_bib0405","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1177\/0269881117705098","article-title":"Have antipsychotics a different speed of action in the acute treatment of mania? A single-blind comparative study","volume":"31","author":"Buoli","year":"2017","journal-title":"J Psychopharmacol."},{"key":"10.1016\/j.rpsm.2018.03.007_bib0410","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/acps.12262","article-title":"A single-dose, randomized, double-blind, placebo-controlled trial of sublingual asenapine for acute agitation","volume":"130","author":"Pratts","year":"2014","journal-title":"Acta Psychiatr Scand."},{"key":"10.1016\/j.rpsm.2018.03.007_bib0415","doi-asserted-by":"crossref","first-page":"27","DOI":"10.64719\/pb.4353","article-title":"Asenapine for the control of physical aggression: A prospective naturalist pilot study","volume":"47","author":"Amon","year":"2017","journal-title":"Psychopharmacol Bull."},{"key":"10.1016\/j.rpsm.2018.03.007_bib0420","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/acps.12262","article-title":"A single-dose, randomized, double-blind, placebo-controlled trial of sublingual asenapine for acute agitation","volume":"130","author":"Pratts","year":"2014","journal-title":"Acta Psychiatr Scand."},{"key":"10.1016\/j.rpsm.2018.03.007_bib0425","first-page":"803","article-title":"Asenapine review, partII: Clinical efficacy, safety and tolerability","volume":"13","author":"Citrome","year":"2014","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.rpsm.2018.03.007_bib0430","first-page":"1145","article-title":"Comparison of somnolence associated with asenapine, olanzapine, risperidone, and haloperidol relative to placebo in patients with schizophrenia or bipolar disorder","volume":"9","author":"Gao","year":"2013","journal-title":"Neuropsychiatr Dis Treat."},{"key":"10.1016\/j.rpsm.2018.03.007_bib0435","first-page":"845","volume":"30","author":"Fang","year":"2016","journal-title":"Antipsychotic drug-induced somnolence: Incidence, mechanisms, and management CNS Drugs"},{"key":"10.1016\/j.rpsm.2018.03.007_bib0440","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.4088\/JCP.v67n0704","article-title":"Associations between bipolar disorder and metabolic syndrome: A review","volume":"67","author":"Taylor","year":"2006","journal-title":"J Clin Psychiatry."},{"key":"10.1016\/j.rpsm.2018.03.007_bib0445","doi-asserted-by":"crossref","first-page":"472","DOI":"10.4088\/JCP.v69n0320","article-title":"Major changes in glucose metabolism, including new-onset diabetes, within 3months after initiation of or switch to atypical antipsychotic medication in patients with schizophrenia and schizoaffective disorder","volume":"69","author":"Van Winkel","year":"2008","journal-title":"J Clin Psychiatry."},{"key":"10.1016\/j.rpsm.2018.03.007_bib0450","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1177\/0269881109102919","article-title":"Evidence-based guidelines for treating bipolar disorder: Revised second edition\u2014recommendations from the British Association for Psychopharmacology","volume":"23","author":"Goodwin","year":"2009","journal-title":"J Psychopharmacol."},{"key":"10.1016\/j.rpsm.2018.03.007_bib0455","doi-asserted-by":"crossref","first-page":"238","DOI":"10.4088\/JCP.12m08271","article-title":"Weight change and metabolic effects of asenapine in patients with schizophrenia and bipolar disorder","volume":"75","author":"Kemp","year":"2013","journal-title":"J Clin Psychiatry."},{"key":"10.1016\/j.rpsm.2018.03.007_bib0460","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/j.2051-5545.2009.tb00199.x","article-title":"Metabolic syndrome in people with schizophrenia: A review","volume":"8","author":"De Hert","year":"2009","journal-title":"World Psychiatry"},{"key":"10.1016\/j.rpsm.2018.03.007_bib0465","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/S1888-9891(08)72513-8","article-title":"Consenso espa\u00f1ol de salud f\u00edsica del paciente con trastorno bipolar","volume":"1","author":"Bobes","year":"2008","journal-title":"Rev Psiquiatr Salud Ment."},{"key":"10.1016\/j.rpsm.2018.03.007_bib0470","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.rpsm.2011.07.003","article-title":"Recomendaciones para el cambio de antipsic\u00f3ticos. Posicionamiento de la Sociedad Espa\u00f1ola de Psiquiatr\u00eda y Sociedad Espa\u00f1ola de Psiquiatr\u00eda Biol\u00f3gica","volume":"4","author":"Bernardo","year":"2011","journal-title":"Rev Psiquiatr Salud Ment."},{"key":"10.1016\/j.rpsm.2018.03.007_bib0475","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/sj.mp.4001556","article-title":"Treatments for schizophrenia: A critical review of pharmacology and mechanisms of action of antipsychotic drugs","volume":"10","author":"Miyamoto","year":"2005","journal-title":"Mol Psychiatry."},{"key":"10.1016\/j.rpsm.2018.03.007_bib0480","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/sj.mp.4002066","article-title":"Atypical antipsychotic-induced metabolic side effects: Insights from receptor-binding profiles","volume":"13","author":"Nasrallah","year":"2008","journal-title":"Mol Psychiatry."},{"key":"10.1016\/j.rpsm.2018.03.007_bib0485","first-page":"92","article-title":"Concomitant medications and possible side effects of antimuscarinic agents","volume":"10","author":"MacDiarmid","year":"2008","journal-title":"Rev Urol."},{"key":"10.1016\/j.rpsm.2018.03.007_bib0490","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.rpsm.2015.11.003","article-title":"Spanish consensus on the risks and detection of antipsychotic drug-related hyperprolactinaemia","volume":"9","author":"Montejo","year":"2016","journal-title":"Rev Psiquiatr Salud Ment."},{"key":"10.1016\/j.rpsm.2018.03.007_bib0495","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1177\/2160763X12455328","article-title":"Asenapine safety, tolerability, and pharmacokinetics after single and multiple doses in healthy volunteers","volume":"1","author":"Dogterom","year":"2012","journal-title":"Clin Pharmacol Drug Dev."},{"key":"10.1016\/j.rpsm.2018.03.007_bib0500","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3371\/CSRP.5.4.6","article-title":"Asenapine: A synthesis of efficacy data in bipolar mania and schizophrenia","volume":"5","author":"McIntyre","year":"2012","journal-title":"Clin Schizophr Relat Psychoses."},{"key":"10.1016\/j.rpsm.2018.03.007_bib0505","first-page":"3007","article-title":"Asenapine for bipolar disorder","volume":"11","author":"Scheidemantel","year":"2015","journal-title":"Neuropsychiatr Dis Treat"},{"key":"10.1016\/j.rpsm.2018.03.007_bib0510","first-page":"247","article-title":"Safety and tolerability of switching to asenapine from other antipsychotic agents: Pooled results from two randomized multicenter trials in stable patients with persistent negative symptoms in schizophrenia","volume":"8","author":"Cazorla","year":"2012","journal-title":"Neuropsychiatr Dis Treat."}],"container-title":["Revista de Psiquiatr\u00eda  y Salud Mental"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1888989118300429?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1888989118300429?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T11:33:20Z","timestamp":1761824000000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1888989118300429"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":51,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["S1888989118300429"],"URL":"https:\/\/doi.org\/10.1016\/j.rpsm.2018.03.007","relation":{},"ISSN":["1888-9891"],"issn-type":[{"value":"1888-9891","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Uso de asenapina en la pr\u00e1ctica cl\u00ednica: recomendaciones de un panel de expertos","name":"articletitle","label":"Article Title"},{"value":"Revista de Psiquiatr\u00eda  y Salud Mental","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rpsm.2018.03.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 SEP y SEPB. Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}